Philip Morris charged over tobacco sticks
The Ministry of Health has charged tobacco giant Philip Morris over the sale of tobacco sticks known as HEETS.
‘We’re becoming a tech company’: The £99 billion cigarette giant behind Lucky Strike is trying to be more like Apple
“We are becoming a tech company,” British American Tobacco (BAT)’s Dr. David O’Reilly told Business Insider during a recent tour of the company’s research and development (R&D) headquarters in Southampton, England.
Trump administration approves delay in FDA e-cigs guidelines
The Trump administration is giving federal health officials more time to evaluate Obama administration-era guidelines on electronic cigarettes, vaporizers and other innovative nicotine and tobacco products.
More than half of UK vapers 'have given up smoking'
For the first time, more than half of the UK's electronic-cigarette users have since given up smoking tobacco, a study suggests.
New Duncan Hunter Draft Legislation
To protect the public health by providing the Food and Drug Administration with certain authority to regulate e-liquids and personal electronic vaporizers, to reduce the morbidity and mortality resulting from cigarette smoking through the responsible regulation of e-liquids and personal electronic vaporizers as a tobacco harm reduction strategy, and for other purposes.

Tobacco Vapor Electronic Cigarette Association

TVECA is an international nonprofit trade association. Our organization is dedicated to creating a sensible and responsible electronic cigarette market by providing the media, legislative bodies and consumers with education, communication and research.

Call: 1 (888) 99-TVECA

Fax: 1 (888) 332-2058

Email: info@tveca.com

Home Variant 2

Dr Konstantinos Farsalinos speaking at the GFN Dialogue

President Donald Trump has nominated Dr. Scott Gottlieb to be the next Commissioner of the FDA

U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday.

If confirmed by the Senate, Gottlieb would be in charge of implementing Trump's plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.

Gottlieb is well known on Capitol Hill, where he has testified multiple times on hot-button health issues, including complex drug pricing matters, and is viewed favorably by drug companies and pharmaceutical investors. He sits on the boards of several small drug and biotech companies and is an adviser to GlaxoSmithKline Plc (GSK.L).

"Thank God it's Gottlieb," Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note. "We view this as a favorable development for the sector."

Gottlieb was chosen over Jim O'Neill, a libertarian investor close to Silicon Valley billionaire Peter Thiel, a PayPal co-founder who now advises Trump on technology and science matters. O'Neill's stated view that drugs should be approved before being proven effective generated widespread alarm.

Gottlieb, 44, is a resident fellow at the conservative American Enterprise Institute think tank and a partner at a large venture capital fund. He is a former FDA deputy commissioner who has advocated a loosening of requirements needed for approval of new medical products.

"Scott knows how the agency works and he will move it forwards, though maybe not always in ways the agency is comfortable with," said John Taylor, a lawyer and president of compliance and regulatory affairs with the consulting firm Greenleaf Health and a former acting FDA deputy commissioner.

In addition to his public health and health policy roles, Gottlieb has for the past decade been a partner at New Enterprise Associates, a large venture fund with investments in the life sciences, medical technology and healthcare services.

Critics of the nomination say Gottlieb's financial background present an array of potential conflicts of interest.

Dr. Michael Carome, director of Public Citizen's Health Research Group, said Gottlieb "has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry." If confirmed, he added, "he will have to be recused from key decisions time and time again."

You can read more Here

TVECA Members

TVECA
Go to top